Purpose: Sentinel node biopsy (SNB) is routinely performed in patients with node-negative early breast cancers to assess the axilla. SNB has no proven therapeutic benefit. SNB contributes significantly to poorer quality of life in early breast cancer patients. There will be substantial improvements in workflow and cost by removing SNB from early breast cancer treatment, and hence, a non-invasive alternative for SNB is highly desirable. The MD Anderson Cancer Centre (MDACC) nomogram predicts the lymph node status based on seven clinicopathological variables. Our study aims to validate this model in an Australian cohort. Methodology: We performed a retrospective analysis of EBC patients presenting to our institution between 2012 and 2020. Data gathered include age, tumour size, lymphovascular invasion (LVI), tumour location, multifocality, histologic type and triple negative receptor status These clinicopathologic variables were entered into the MDACC nomogram. The models ' receiver operating characteristics (ROC) curve was created, and the area under the curve (AUC) was computed. Results: 1121 patients were eligible for the study. The mean age of the population was 61 years. 83 % of all SNBs were negative. The model's accuracy in predicting the sentinel node status in an individual case is moderate. Conclusion: The MDACC nomogram is a preoperative tool to support decision-making for clinicians managing EBCs. This tool was validated in a large cohort of Australian patients.